Axon Stock Bounces Back: Analysts Say Buy the Dip

Axon Enterprise stock took investors on a wild ride this week. After plunging 10% on Tuesday to an 18-month low, the shares roared back on Wednesday, jumping as much as 10.7% before settling with a gain of over 4%. The initial drop seemed puzzling, with no major company-specific news, though it may have been linked to its ongoing Axon Week conference or an upcoming court hearing about its new headquarters.

The sharp rebound was fueled by a combination of a broader market lift from geopolitical news and, more importantly, a wave of supportive analyst commentary. Several Wall Street firms issued notes in response to presentations and customer panels at Axon Week.

Leading the charge, TD Cowen maintained its buy rating on the stock. While it lowered its price target from $950 to $825 in light of the recent price decline, the analyst called the customer feedback "very bullish" and attributed the prior day's sell-off to "non-fundamental factors."

Other major firms, including Morgan Stanley and Goldman Sachs, also issued bullish notes, urging investors to buy the stock on weakness. This collective vote of confidence from analysts provided the catalyst for the significant intraday recovery.

The stock gave back some of its early gains by the afternoon, but the powerful rebound signaled that institutional investors saw value after the steep decline, setting the stage for a potential shift in sentiment.

For investors, this episode highlights the difference between price movements driven by sentiment and those grounded in business fundamentals. The 10% crash lacked a clear fundamental cause, making it look like an emotional or technical sell-off. The rapid recovery on analyst support suggests the market is quickly correcting that mistake.

The analyst notes are crucial because they are based on fresh, firsthand insights from Axon's key event. When multiple firms independently conclude that the business outlook remains strong and the sell-off was overdone, it adds significant credibility to the rebound. It indicates that the core investment thesis for Axon—its leading position in public safety technology—remains intact.

From a valuation perspective, the drop pushed Axon's price-to-sales ratio down to around 10, near its lowest level since 2023. This makes the stock appear historically cheap if its growth prospects are unchanged. The bounce suggests the market is beginning to recognize this disconnect.

Looking ahead, the story isn't over. The Axon Week conference continues, and a court hearing regarding its headquarters begins on Friday. These events could introduce new volatility. However, the strong analyst defense establishes a floor of fundamental support, making the stock more attractive for those who believe in the long-term story and can tolerate short-term noise.